ストックスクリーナーアプリを入手
5.04
0.00%
0.00
アフターアワーズ：
5.04
Atara Biotherapeutics Inc (ATRA) 最新ニュース
Highs Report: What analysts say about Atara Biotherapeutics Inc stockMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Fundamentals Check: Does Nuveen Churchill Direct Lending Corp have pricing powerJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Can Atara Biotherapeutics Inc stock double in the next yearMarket Activity Report & Accurate Intraday Trade Tips - baoquankhu1.vn
Is Atara Biotherapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Reliable Breakout Stock Forecasts - Mfd.ru
Surprises Report: Will Atara Biotherapeutics Inc benefit from green energy policiesJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Chartmill
Price-Driven Insight from (ATRA) for Rule-Based Strategy - Stock Traders Daily
Short Squeeze: Can Atara Biotherapeutics Inc weather a recessionJuly 2025 WrapUp & Low Drawdown Trading Techniques - baoquankhu1.vn
Patterns Watch: Can Atara Biotherapeutics Inc weather a recessionMarket Sentiment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - FinancialContent
What momentum indicators show for Atara Biotherapeutics Inc. stockMarket Rumors and News & Trusted Financial Advisors at No Cost - bollywoodhelpline.com
FDA Again Rejects Atara - labusinessjournal.com
Analyst Calls: Can Ligand Pharmaceuticals Incorporated beat the S P 5002025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Summary: Will HAFN benefit from green energy policiesStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock - Defense World
(ATRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Atara Bio director Huang James sells $489k in shares By Investing.com - Investing.com Australia
Atara Bio director Huang James sells $489k in shares - Investing.com
Aug Selloffs: Is Atara Biotherapeutics Inc being accumulated by smart moneyTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel - FinancialContent
Entry Recap: Is Atara Biotherapeutics Inc stock dividend yield sustainableJuly 2025 Retail & Daily Profit Maximizing Tips - Bộ Nội Vụ
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Atara Biotherapeutics' EBVALLO BLA Rejected by FDA, Stock Plummets 57% - Intellectia AI
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
FDA Rejects Atara's (ATRA) Ebvallo BLA: Calls for New Evidence o - GuruFocus
US FDA declines to approve Atara’s therapy for rare blood cancer - PharmaLive
Atara's cell therapy is again rejected by FDA, cites agency reversing position on single-arm study - Endpoints News
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy By Investing.com - Investing.com Canada
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form - TipRanks
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy - Investing.com
FDA says no to rare transplant cancer treatment patients awaited - Stock Titan
1.22%
2.07%
大文字化:
|
ボリューム (24 時間):